Searchable abstracts of presentations at key conferences in endocrinology

ea0009p230 | Clinical | BES2005

Differential regulation of Urocortin 3 mRNA expression in the central nervous system by stress and glucocorticoids

Jamieson P , Li C , Vaughan J , Vale W

The CRF-related ligand Urocortin 3 (Ucn 3) is expressed in discrete subcortical areas with highest mRNA levels in the medial amgydala (MEA), hypothalamic median preoptic nucleus (MePO) and the rostral part of the perifornical hypothalamic area (PFN). Close anatomical association between major Ucn 3 terminal fields and the type 2-CRF receptor in hypothalamus, lateral septum and medial amygdala suggest it is well placed to modulate physiological processes including behavioural, ...

ea0007s3 | Society for Endocrinology Dale Medal Lecture | BES2004

Corticotropin releasing factor (CRF) family of ligands and their receptors

Vale W , Bale T , Li C , Reyes T , Perrin M , Jamieson P , Chen A , Brar B , Vaghan J , Rivier J

CRF mediates numerous complementary stress-related endocrine (HPA), autonomic and behavioral responses. CRF antagonists block many stress-induced responses in experimental animals. Furthermore, perturbations of the CRF system or HPA have been reported in human affective disorders. CRF acts through two Class B G protein coupled receptors derived from two genes, which have alternative splice variants and distinct expression patterns. Mice null for CRF-R1 exhibit reduced basal an...

ea0011p407 | Diabetes, metabolism and cardiovascular | ECE2006

Urocortin 2 mediates glucose utilization and insulin sensitivity in skeletal muscle

Chen A , Brar B , Choi CS , Rousso D , Vaughan J , Donaldson C , Smith S , Li C , Kim SN , Nagy T , Shulman G , Lee KF , Vale W

Skeletal muscle is the principal tissue responsible for insulin-stimulated glucose disposal and is thus the major site of peripheral insulin resistance. Urocortin 2 (Ucn2), a corticotropin releasing factor (CRF) family member and the type 2 CRF receptor (CRFR2) are highly expressed in skeletal muscle. To determine the physiological role of Ucn2, we generated mice deficient in this peptide. Using glucose and insulin tolerance tests and hyperinsulinemic euglycemic glucose clamp ...

ea0007p47 | Diabetes, metabolism and cardiovascular | BES2004

A novel non-steroidal inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 improves features of metabolic syndrome in murine disease models

Thieringer R , Balkovec J , Chen H , Frazier E , Le Grand C , Li Z , Metzger J , Mundt S , Nunes C , Strowski M , Olson S , Robertson N , Strack A , Schaeffer J , Wright S , Zhang B , Hermanowski-Votska A

Chronic exposure to elevated circulating glucocorticoids can lead to metabolic changes, which resemble those observed in Metabolic Syndrome. Features of the Metabolic Syndrome can be reversed by lowering systemic glucocorticoid levels or by treatment with a glucocorticoid receptor antagonist. At the intracellular level, exposure to glucocorticoids is regulated by two distinct 11beta-hydroxysteroid dehydrogenases, 11beta-HSD type 1 and type 2. 11beta-HSD1 predominantly acts as ...

ea0098b15 | Basic Science | NANETS2023

Investigating serotonin metabolism in neuroendocrine cancers

Tow Dane H. , Ridder Maclain , Tran Catherine G. , Borbon Luis C. , Li Guiying , Kaemmer Courtney A. , Abusada Ellen , Harish Mahalingam Aswanth , Sadanandam Anguraj , Chandrasekharan Chandrikha , Dillon Joseph , Spitz Douglas R. , Quelle Dawn E. , H.F. Chan Carlos , Bellizzi Andrew , Howe James R. , Po Hien Ear and

Background: Small bowel neuroendocrine tumors (SBNETs) originate from enterochromaffin cells in the intestine which synthesize and secrete serotonin. Other NETs and other cancers may also produce serotonin but do not store them in vesicles. The rate limiting enzyme of serotonin biosynthesis is tryptophan hydroxylase 1 (Tph1). Patients with high serotonin level could develop carcinoid syndrome, which can be treated with somatostatin analogues and the Tph1 inhibitor telotristat ...